ClinicalTrials.gg
CompletedNCT06216626PRIMEUpdated Jul 23, 2024

PRebiotic Intervention for Metabolic and MEntal Health (PRIME)

An interventional study of myota's prebiotic fibre blend in Metabolic Syndrome, Anxiety and Mood, sponsored by Myota GmbH. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-23.

Sponsored by Myota GmbH · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jun 2023, registered Jan 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Metabolic Syndrome with a site in United Kingdom — 9 open to participants now, 10 under way, none of them phase 3. Metabolic Syndrome · United Kingdom.

Enrollment
19th of 48
60 · median 45
Started
2023
with 2 others
No phase
40 of 55
6 open now
Registered
45th of 55
by date

Among the 55 studies in Metabolic Syndrome with a site in United Kingdom, this one is the 19th largest by enrollment of the 48 interventional ones that give a count, is one of 3 that started in 2023, is one of 40 with no phase, and was the 45th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

9 of the 55 studies in Metabolic Syndrome with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Metabolic Syndrome with a site in United Kingdom, or all of them as a file.
02

Study summary

The purpose of the study is to determine whether a daily prebiotic fibre blend can reduce systemic inflammation, dyslipidemia, and self-report measures of mental health in individuals with metabolic syndrome. This study will help shape a larger randomised controlled study (RCT) powered to assess efficacy in a bigger cohort of patients.

Primary outcome measures will explore the efficacy of a prebiotic fibre blend on systemic inflammation. Secondary and exploratory outcomes measures will explore the efficacy of the prebiotic blend on clinical biomarkers associated with cardiometabolic risk factors, microbiota features, and mental health. Using these data, we will also estimate in-year savings for the NHS in the metabolic syndrome population on a per participant basis.

Read the detailed description

Metabolic syndrome is not a chronic disease, but a cluster of metabolic abnormalities including central obesity, insulin resistance, hyperglycemia, hypertension, and dyslipidemia. In the UK, it's estimated that 1 in 3 adults aged 50 years or over meets the criteria of metabolic syndrome. Emerging evidence suggests that metabolic syndrome is associated with low-grade systemic inflammation, which is thought to play a critical role in the subsequent pathogenesis of various metabolic and cardiovascular diseases. In fact, the inflammatory biomarker, high-sensitivity (hs)-CRP, has been shown to be predictive of whether metabolic syndrome progresses to a chronic disease, including cardiovascular disease (CVD), type 2 diabetes (T2D), and cancer mortality. Alongside metabolic disturbances, recent studies have shown that repeated (or long-term) exposure to systemic inflammation is also associated with an increased risk of future depressive and anxiety symptoms, potentially acting via the blood-brain barrier (BBB) interface.

From both a physical and mental health standpoint, it's clear that novel interventions, beyond pharmacotherapy, are needed to reverse the progression of metabolic syndrome, and reduce the risk of developing a long-term chronic disease, and poor mental health.

It is well established that dietary fibre plays a critical role in reducing symptoms of metabolic syndrome, including improvements in insulin sensitivity, glucose metabolism, lipid profile, and blood pressure. Specifically, dietary fibre has been shown to reduce cholesterol levels by binding to bile acids and promoting their excretion, as well as by decreasing the absorption of dietary cholesterol. Additionally, dietary fibre can slow the absorption of carbohydrates and reduce post-prandial glucose spikes, which may contribute to improvements in insulin sensitivity and metabolic health.

Growing evidence also suggests that the mechanisms underlying the benefits of fibre are thought to be mediated, at least in part, by the gut microbiota and their metabolites, such as short-chain fatty acids (SCFAs). A recent systematic review and meta-analysis of 10 randomised controlled trials found that increased intake of dietary fibre was associated with significant improvements in fasting glucose, insulin resistance, total cholesterol, and low-density lipoprotein (LDL) cholesterol levels in individuals with type 2 diabetes. Furthermore, a randomised controlled trial in individuals with metabolic syndrome found that supplementation with a prebiotic fibre blend led to significant reductions in fasting glucose, insulin resistance, and inflammatory markers. Therefore, increasing prebiotic fibre intake may represent a promising strategy for the prevention and management of metabolic symptoms, but remains poorly understood.

Prebiotics are specific types of fibres found in foods like onion, garlic, artichokes, asparagus, leeks, and chicory root. However, to reap the benefits of prebiotics for given health indications, this requires someone to consume roughly 5-10 onions a day. Prebiotic fibre blends (in powder form) are derived from a diversity of plant-based sources, and allows for the study of prebiotic-based benefits in a feasible, easy, measurable, and controlled way.

In this current study, we aim to assess the effects of a daily prebiotic fibre blend on systemic inflammation, the gut microbiome, lipid profiles, and self-report measures of mental health in individuals with metabolic syndrome. The study will be conducted over 12 weeks, and the findings may provide new insights into the potential role of prebiotics in the prevention and management of physical and mental health risk factors associated with chronic disease.

The study population will include adults aged 18-75 years who meet the criteria for metabolic syndrome. To promote the inclusion and diversity of participants across England, this study will be conducted remotely, by posting participants the at-home collection kits (stool and finger prick tests) and online surveys. This gives access to participants who would otherwise not be able to take part in research.

03

Conditions studied

  • Metabolic Syndrome
  • Anxiety
  • Mood
  • Stress

Keywords

  • gut microbiome
  • inflammation
  • mental health
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged 18-75 years with a diagnosis of Metabolic Syndrome (MetS), yet not receiving treatment for their symptoms
  • MetS is diagnosed using the IDF criteria (Alberti, Zimmet \& Shaw, 2006). MetS is defined as having abdominal obesity (waist circumference ≥ 94 cm in men, and ≥ 80 cm in women) plus two or more of the following: raised triglycerides (≥1.7 mmol/L); reduced HDL-C (\< 1.03 mmol/L in men and \< 1.29 mmol/L in women); raised systolic blood pressure (≥ 130 mmHg); raised diastolic blood pressure (≥ 85 mmHg); treatment of previously diagnosed hypertension; raised fasting plasma glucose (≥ 5.6 mmol/L); or previously diagnosed with pre-diabetes.
  • Capacity to give
  • Ability to comply with study requirements.

Exclusion criteria

Exclusion Criteria:

  • Includes a current diagnosis of Type 1 or 2 diabetes or cardiovascular disease
  • receiving medications that lower cholesterol, blood pressure, or blood glucose levels
  • pregnancy, lactation, or an intent to become pregnant during the course of the study
  • continuous antibiotic use for > 3 days within 1 month prior to enrolment
  • continuous use of weight-loss drug for > 1 month before screening
  • major change in dietary intake in past month (e.g. excluding whole food groups)
  • currently consuming large doses of prebiotic or probiotic supplements
  • prior use (\< 6 months) of any blood glucose or cholesterol lowering medication
  • a significant gastrointestinal (GI) condition affecting absorption including (but not limited to) inflammatory bowel disease; weight loss surgery
  • irritable bowel disease
  • end stage renal disease
  • active cancer, or treatment for any cancer, in last 3 years.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Prebiotic fibre

    The treatment group will consume 10g per day of a diverse prebiotic fibre supplement. Supplements are powdered and unflavoured, and given to the participants in 300g packets lasting for 30 days. A 10g scoop is included in each packet and participants are advised to consume one level scoop at any time of the day. Participants are provided with examples on how to consume the supplement (e.g., breakfast cereal, coffee, tea, water).

    Dietary Supplement: myota's prebiotic fibre blend

  • Active comparator
    Control

    Participants are provided with standard of care (dietary advice). Recommendations for diet and lifestyle advice are provided by a UK-registered GP, and follow the Heart UK's Healthy Eating Guidelines. These recommendations emphasise a Mediterranean diet, rich in fruit, vegetables, and healthy fats (omega-3 fatty acids), while reducing refined sugar, salt, processed foods, and alcohol intake. The Mediterranean diet is considered a gold-standard for participants with MetS and poor mental health.

    Dietary Supplement: myota's prebiotic fibre blend

Interventions

  • Dietary supplementmyota's prebiotic fibre blend

    Each 10g daily serve of supplement contains the following fibres: * Fructooligosaccharides * Inulin * Resistant dextrin * Resistant maltodextrin * Partially hydrolysed guar gum * Guar gum

06

What researchers measure

Primary outcomes

  1. C-Reactive Protein

    To compare the effect of Myota's prebiotic fibre blend versus standard of care on C-Reactive Protein levels

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Depression, Anxiety and Stress Scale (42-item)

    To compare the effect of Myota's prebiotic fibre blend versus standard of care on Depression, Anxiety and Stress Scale (42-item) scores. Minimum score = 0, maximum score = 126, where higher scores indicate worse outcomes.

    Time frame: Baseline and Week 12

  2. Patient Health Questionnaire (PHQ)

    To compare the effect of Myota's prebiotic fibre blend versus standard of care on Patient Health Questionnaire scores. Minimum score = 1, maximum score = 27, where higher scores indicate worse outcomes.

    Time frame: Baseline and Week 12

  3. Perceived Stress Scale (PSS)

    To compare the effect of Myota's prebiotic fibre blend versus standard of care on Perceived Stress Scale scores. Minimum score = 0, maximum score = 40, where higher scores indicate worse outcomes.

    Time frame: Baseline and Week 12

  4. Generalised Anxiety Disorder (GAD) Scale

    To compare the effect of Myota's prebiotic fibre blend versus standard of care on Generalised Anxiety Disorder Scale scores. Minimum score = 0, maximum score = 21, where higher scores indicate worse outcomes.

    Time frame: Baseline and Week 12

  5. Gastrointestinal Symptom Rating Scale (GSRS)

    To compare the effect of Myota's prebiotic fibre blend versus standard of care on Gastrointestinal Symptom Rating Scale scores. Scores are calculated for 5 sub-categories: reflux, pain, constipation, diarrhoea, indigestion, where the minimum score is 1 and maximum score is 21, where higher scores indicate worse outcomes.

    Time frame: Baseline and Week 12

  6. Gut Microbiome Profiles

    To compare the effect of Myota's prebiotic fibre blend versus standard of care on gut microbiome profiles

    Time frame: Baseline and Week 12

  7. Lipid Profiles

    To compare the effect of Myota's prebiotic fibre blend versus standard of care on lipid profiles

    Time frame: Baseline and Week 12

  8. Diastolic blood pressure

    To compare the effect of Myota's prebiotic fibre blend versus standard of care on diastolic blood pressure.

    Time frame: Baseline and Week 12

  9. Systolic Blood pressure

    To compare the effect of Myota's prebiotic fibre blend versus standard of care on systolic blood pressure.

    Time frame: Baseline and Week 12

Other outcomes

  1. Dietary fibre intake

    Assess the difference in dietary fibre intake as a confounding variable.

    Time frame: Baseline and Week 12

07

Study locations

1 site
  • Myota Health
    London, EC1N 2SW, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — De-identified participants data may be available to other researchers upon reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Dec 2023, 6 months.

Of 50 industry-sponsored interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's 6 months is below that.

Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2024
First posted
Jan 22, 2024
StartActual
Jun 19, 2023
Primary completionActual
Dec 22, 2023
CompletionActual
Dec 22, 2023
Last update
Jul 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06216626
Lead sponsor
Myota GmbH
Responsible party
Sponsor
First posted
Jan 22, 2024
Start date
Jun 19, 2023
Primary completion
Dec 22, 2023
Completion
Dec 22, 2023
Last update
Jul 23, 2024

Study contacts

Caitlin V Hall, PhD
principal investigator · myota health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion